Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Joseph M KimDeepak L BhattSamuel Dagogo-JackDavid Z I CherneyFrancesco CosentinoDarren K McGuireRichard E PratleyChih-Chin LiuNilo B CaterRobert C FrederichJames P MancusoChristopher P CannonPublished in: Diabetes, obesity & metabolism (2023)